Display options
Cite
Brandwein JM, Smith AM, Langley GR, et al. Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation. Leuk Lymphoma. 1991;4(4):231-8doi: 10.3109/10428199109068071.
Brandwein, J. M., Smith, A. M., Langley, G. R., Burnell, M., Sutcliffe, S. B., & Keating, A. (1991). Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation. Leukemia & lymphoma, 4(4), 231-8. https://doi.org/10.3109/10428199109068071
Brandwein, J M, et al. "Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation." Leukemia & lymphoma vol. 4,4 (1991): 231-8. doi: https://doi.org/10.3109/10428199109068071
Brandwein JM, Smith AM, Langley GR, Burnell M, Sutcliffe SB, Keating A. Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation. Leuk Lymphoma. 1991;4(4):231-8. doi: 10.3109/10428199109068071. PMID: 27463042.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 1991;4(4):231-8. doi: 10.3109/10428199109068071.

Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation.

Leukemia & lymphoma

J M Brandwein, A M Smith, G R Langley, M Burnell, S B Sutcliffe, A Keating

Affiliations

  1. a University of Toronto Autologous Bone Marrow Transplant Program, Toronto Hospital, Toronto, Ontario.
  2. b London Regional Cancer Centre, London, Ontario.
  3. c Victoria General Hospital, Halifax, Nova Scotia.
  4. d Saint John Regional Hospital, Saint John, New Brunswick, Canada.

PMID: 27463042 DOI: 10.3109/10428199109068071

Abstract

Fifty-one patients with relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma were referred for autologous bone marrow transplantation (ABMT). The primary criterion for eligibility was sensitivity to conventional-dose salvage chemotherapy. Of 47 patients who received salvage chemotherapy, 30 demonstrated chemotherapy-sensitive disease. Six eligible patients did not undergo ABMT for various reasons. A total of 24 patients underwent ABMT, with etoposide, melphalan ± total body irradiation as the intensive therapy regimen. There was one early treatment-related death and three non-responders. Of the remaining patients, 9 relapsed, while 11 remain in continuous complete remission (CR) at a median follow-up of 21 months after transplant (range 5-37 months). Two patients with chemosensitive disease and bone marrow involvement underwent allogeneic BMT with marrow from HLA-identical siblings. Both are in continuous CR at 6 and 12 months follow-up. Of the 25 patients who did not undergo ABMT, all have died (median survival 5 months). The results indicate that approximately one-half of relapsed or refractory aggressive histology lymphoma patients referred for ABMT eventually undergo transplantation, if chemotherapy-sensitive relapse is the major criterion for eligibility. Approximately 25% of the referred patients may become long-term disease-free survivors with this approach. Reports of marrow transplant series should include all patients referred for ABMT as the denominator for calculating disease-free survival in order to reduce the bias of patient selection.

Keywords: Non-Hodgkin's lymphoma; autologous marrow transplant; salvage chemotherapy

Publication Types